NYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $13.44 +0.02 (+0.11%) Closing price 03:59 PM EasternExtended Trading$13.41 -0.02 (-0.16%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Organon & Co. Stock (NYSE:OGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Organon & Co. alerts:Sign Up Key Stats Today's Range$13.42▼$13.4650-Day Range$5.71▼$13.4752-Week Range$5.69▼$13.48Volume2.12 million shsAverage Volume7.77 million shsMarket Capitalization$3.53 billionP/E Ratio14.45Dividend Yield0.60%Price Target$11.40Consensus RatingReduce Company Overview Organon & Co. is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co. in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact. In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies. The company’s offerings extend to emerging areas such as endometriosis and osteoporosis, underscoring its commitment to advancing care for women throughout various life stages. This specialized focus leverages decades of research and clinical experience inherited from its predecessor organization. Organon’s biosimilars division develops and markets lower-cost versions of complex biologic therapies. Its pipeline includes multiple biosimilar candidates designed to increase patient access to treatments for autoimmune disorders and other serious conditions. By combining in-house development capabilities with strategic partnerships, Organon aims to build a sustainable biosimilars business that complements its branded product lines. With operations spanning more than 140 countries, Organon serves diverse markets across North America, Europe, Latin America, Asia and emerging regions. The company is led by President and Chief Executive Officer Kevin Ali, who oversees global strategy and operations. Organon’s corporate vision emphasizes innovation, patient-centricity and the responsible stewardship of its legacy products to drive long-term growth and healthcare advancement. AI Generated. May Contain Errors. Read More Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreOGN MarketRank™: Organon & Co. scored higher than 62% of companies evaluated by MarketBeat, and ranked 344th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingOrganon & Co. has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 2 sell ratings.Downside RiskOrganon & Co. has a consensus price target of $11.40, representing about 15.1% downside from its current price of $13.44.Amount of Analyst CoverageOrganon & Co. has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.50% Earnings GrowthEarnings for Organon & Co. are expected to grow by 6.50% in the coming year, from $3.23 to $3.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 14.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 14.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.99.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOrganon & Co. has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Organon & Co.'s valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.55% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 0.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently increased by 4.75%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldOrganon & Co. has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 8.60%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.33% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. News and Social Media2.9 / 5News Sentiment0.67 News SentimentOrganon & Co. has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Organon & Co. this week, compared to 8 articles on an average week.Search Interest23 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $353,081.00 in company stock, which represents 0.0100% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have bought more of their company's stock than they have sold. Specifically, they have bought $353,081.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.62% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGN Stock News HeadlinesHanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast AsiaMay 21 at 5:06 AM | globenewswire.comOrganon & Co. (NYSE:OGN) Receives $11.40 Average Price Target from AnalystsMay 21 at 3:33 AM | americanbankingnews.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 22 at 1:00 AM | Porter & Company (Ad)Deep value mid-caps: 10 names trading at single-digit forward P/EsMay 18, 2026 | seekingalpha.comOrganon to Present New Research on Access and Value at ISPOR 2026May 15, 2026 | businesswire.comOrganon Buyout By Sun Pharma Shifts Focus To Cash Value And TimingMay 8, 2026 | finance.yahoo.comOrganon & Co. (NYSE:OGN) SVP Lynette Holzbaur Buys 26,448 SharesMay 8, 2026 | insidertrades.com$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQMay 5, 2026 | globenewswire.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $7.17 at the beginning of the year. Since then, OGN shares have increased by 87.4% and is now trading at $13.4350. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) issued its quarterly earnings results on Thursday, April, 30th. The company reported $0.71 EPS for the quarter, missing the consensus estimate of $0.83 by $0.12. The business's quarterly revenue was down 3.5% compared to the same quarter last year. Who are Organon & Co.'s major shareholders? Top institutional shareholders of Organon & Co. include Dimensional Fund Advisors LP (1.24%), First Trust Advisors LP (1.23%), Bank of New York Mellon Corp (0.85%) and Principal Financial Group Inc. (0.48%). Insiders that own company stock include Kevin Ali, Matthew M Walsh, Lynette Holzbaur, Kirke Weaver and Daniel Karp. View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM). Company Calendar Record date for 3/12 Dividend2/23/2026Ex-Dividend for 3/12 Dividend2/23/2026Dividend Payable3/12/2026Last Earnings4/30/2026Record date for 6/11 Dividend5/11/2026Ex-Dividend for 6/11 Dividend5/11/2026Today5/22/2026AGM 20266/09/2026Dividend Payable6/11/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 OGN's financial health is in the Green zone, according to TradeSmith. OGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone551-430-6900FaxN/AEmployees10,000Year Founded2020Price Target and Rating Average Price Target for Organon & Co.$11.40 High Price Target$14.00 Low Price Target$8.00 Potential Upside/Downside-15.1%Consensus RatingReduce Rating Score (0-4)1.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.93 Trailing P/E Ratio14.45 Forward P/E Ratio4.16 P/E Growth1.25Net Income$187 million Net Margins3.99% Pretax Margin8.71% Return on Equity99.95% Return on Assets6.22% Debt Debt-to-Equity Ratio9.47 Current Ratio1.97 Quick Ratio1.42 Sales & Book Value Annual Sales$6.22 billion Price / Sales0.57 Cash Flow$5.79 per share Price / Cash Flow2.32 Book Value$3.44 per share Price / Book3.91Miscellaneous Outstanding Shares262,600,000Free Float258,347,000Market Cap$3.53 billion OptionableNot Optionable Beta1.57 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:OGN) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
